These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28543368)

  • 21. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N; Minami S; Fujii M
    Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
    Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
    Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
    Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
    [No Abstract]   [Full Text] [Related]  

  • 24. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
    Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signet ring cell carcinoma of the eyelid - the monocle tumour.
    Mortensen AL; Heegaard S; Clemmensen O; Prause JU
    APMIS; 2008 Apr; 116(4):326-32. PubMed ID: 18397469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.
    Kreher NC; Pescovitz OH; Delameter P; Tiulpakov A; Hochberg Z
    J Pediatr; 2006 Sep; 149(3):416-20. PubMed ID: 16939760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
    Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Unreliable survival analysis].
    Tretli S; Kvåle R; Hernes E
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
    [No Abstract]   [Full Text] [Related]  

  • 33. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of primary signet-ring cell/histiocytoid carcinoma of the eyelid: immunohistochemical comparison with the normal sweat gland and review of the literature.
    Iwaya M; Uehara T; Yoshizawa A; Kobayashi Y; Momose M; Honda T; Ota H
    Am J Dermatopathol; 2012 Dec; 34(8):e139-45. PubMed ID: 22935888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
    J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
    Lenz AM; Shulman D; Eugster EA; Rahhal S; Fuqua JS; Pescovitz OH; Lewis KA
    Pediatrics; 2010 Sep; 126(3):e728-33. PubMed ID: 20713483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Incorrect about hormone treatment in prostatic cancer].
    Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
    [No Abstract]   [Full Text] [Related]  

  • 38. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
    J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Taneja SS
    J Urol; 2013 Sep; 190(3):880. PubMed ID: 23931194
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.